心室頻脈 – Medxy AI

Reducing Procedure Time with CT-Guided Catheter Ablation in Ventricular Tachycardia: Insights from the InEurHeart Trial

By MedXY 07/04/2026

The InEurHeart trial demonstrates that computed tomography-guided ventricular tachycardia ablation significantly reduces procedure duration while maintaining safety and efficacy compared to conventional methods in patients with ischemic cardiomyopathy.

Cardiology news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Findings from the ALLEVIATE-HF Trial

By MedXY 06/10/2026

Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.

Cardiology news Radiology

Understanding Scar Evolution: How Post-Ablation Cardiac MRI Predicts Long-Term Outcomes in Ventricular Tachycardia

By MedXY 03/07/2026

The PAM-VT 2 study reveals that cardiac MRI (LGE-CMR) performed 3 to 6 months after ventricular tachycardia ablation can accurately predict long-term recurrence risks by analyzing scar stability and conducting channels.

Cardiology news Radiology

Mapping the Maze: How 3D Imaging is Transforming VT Ablation in Congenital Heart Disease

By MedXY 03/03/2026

The CORECA study reveals that preprocedural 3D anatomic and substrate reconstruction from CT or MRI effectively identifies ventricular tachycardia targets in complex congenital heart disease, achieving 87.5% concordance with electroanatomical mapping and high interobserver reproducibility.

Cardiology news

High-Voltage Focal Pulsed Field Ablation Achieves Transmurality and 98% Reduction in Scar-Related Ventricular Tachycardia

By MedXY 01/18/2026

The first-in-human VCAS trial demonstrates that high-voltage focal pulsed field ablation (PFA) safely delivers transmural lesions in thick ventricular scar tissue, significantly reducing ventricular tachycardia burden by 98% in high-risk patients with ischemic and non-ischemic substrates.

Cardiology news

Precision Risk Assessment in CPVT: New Validated Models Predict Arrhythmic Events on Beta-Blocker Therapy

By MedXY 01/03/2026

A landmark study has developed and validated the first clinical risk prediction models for RYR2-mediated CPVT, identifying key factors like age at treatment and prior symptoms that determine life-threatening outcomes despite beta-blocker therapy.